RxDoctor Payments Data

Alex Sieg, MD

Internal Medicine · Davenport, IANPI 1417449570

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,501, more than ten times the $118 reported in 2023. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,181in general payments, 2019–2025

Across 171 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$418
  • Myriad Genetic Laboratories, Inc.$313
  • AbbVie$276
  • Regeneron Healthcare Solutions, Inc.$267
  • Daiichi Sankyo Inc.$267
  • AstraZeneca$235
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,11798%
  • Education$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,181 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$63,610
Medicare patients
241
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole25$485
Oxycodone Hcl19$311
Dexamethasone17$280
Acyclovir29$263
Prochlorperazine Maleate25$214
Ondansetron Hcl22$208
Ondansetron OdtOndansetron19$206
Levofloxacin11$54
Prednisone14$32

Paid to pharmacies, not to this prescriber.

Other internal medicine in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →